View the latest news and SEC filings
Scroll to
LONDON and RALEIGH, N.C., Oct. 21, 2024 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for the third quarter ended September 30, 2024 on Monday, November 4, 2024 and host an investment community conference
Data support Ohtuvayre™ (ensifentrine), as a first-in-class, selective, dual inhibitor of PDE3 and PDE4 in a broad COPD population LONDON and RALEIGH, N.C., Sept. 30, 2024 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces four oral presentations and
One oral presentation and three posters support Ohtuvayre™ (ensifentrine), as a first-in-class, selective, dual inhibitor of PDE3 and PDE4 LONDON and RALEIGH, N.C., Sept. 05, 2024 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces one oral presentation
Ohtuvayre TM (ensifentrine) now available; patient shipments started Strong balance sheet supports commercialization and pipeline expansion Conference call today at 9:00 a.m. EDT / 2:00 p.m. BST LONDON and RALEIGH, N.C., Aug. 08, 2024 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona
| Date | Form | Filing Group | ||
|---|---|---|---|---|
|
May 1, 2017 |
CT ORDER |
CT ORDER |
Other |
|
|
April 28, 2017 |
Securities offered to employees pursuant to employee benefit plans |
S-8 |
Registration Statements |
|
|
April 28, 2017 |
Form of prospectus disclosing information facts events covered in both forms 424B1 424B3 |
424B4 |
Registration Statements |
|
|
April 26, 2017 |
CORRESP |
CORRESP |
Other |
|
|
April 26, 2017 |
UPLOAD |
UPLOAD |
Other |
|
|
April 26, 2017 |
EFFECT |
EFFECT |
Other |
|
|
April 26, 2017 |
EFFECT |
EFFECT |
Other |
|
|
April 26, 2017 |
Registration of up to an additional 20% of securities for an offering filed on an F-1 |
F-1MEF |
Registration Statements |
|
|
April 26, 2017 |
This filing is a pre-effective amendment to an F-1 filing |
F-1/A |
Registration Statements |
Verona Pharma (Nasdaq:VRNA) is focused on delivering our strategy and creating value for shareholders.
